Royal Bank of Canada Has Lowered Expectations for Bausch Health Companies (NYSE:BHC) Stock Price

Bausch Health Companies (NYSE:BHC) had its price target lowered by equities researchers at Royal Bank of Canada from $11.00 to $10.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank of Canada’s price target indicates a potential upside of 35.04% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Evercore ISI raised Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Bausch Health Companies currently has a consensus rating of “Hold” and a consensus price target of $7.58.

Bausch Health Companies Stock Down 0.9 %

Shares of BHC traded down $0.07 during midday trading on Thursday, reaching $7.41. 103,836 shares of the stock were exchanged, compared to its average volume of 2,968,469. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46. The company has a market cap of $2.68 billion, a P/E ratio of -15.43 and a beta of 0.69. The stock’s 50 day simple moving average is $7.79 and its 200 day simple moving average is $7.46.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. The firm had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The business’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.03 earnings per share. As a group, analysts predict that Bausch Health Companies will post 3.73 earnings per share for the current year.

Institutional Trading of Bausch Health Companies

A number of institutional investors have recently added to or reduced their stakes in the stock. Tobam lifted its holdings in Bausch Health Companies by 10.4% during the 4th quarter. Tobam now owns 15,034 shares of the company’s stock worth $121,000 after purchasing an additional 1,422 shares in the last quarter. DGS Capital Management LLC purchased a new stake in shares of Bausch Health Companies in the 4th quarter valued at about $143,000. SG Americas Securities LLC raised its holdings in shares of Bausch Health Companies by 62.0% in the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock valued at $26,614,000 after acquiring an additional 1,263,706 shares in the last quarter. Merit Financial Group LLC purchased a new stake in shares of Bausch Health Companies in the 4th quarter valued at about $228,000. Finally, Sanders Morris Harris LLC raised its holdings in shares of Bausch Health Companies by 16.0% in the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock valued at $234,000 after acquiring an additional 4,000 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.